Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.25+0.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMVT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue progressing IMVT-1402 clinical trials in Graves' disease, myasthenia gravis, CIDP, D2T RA, Sjögren's disease, and cutaneous lupus erythematosus.
Stated as a priority in 2 of last 2 quarters. Management reports all IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected from 2026 through 2028. This consistent restatement and clinical progress indicate delivering on the development timeline priority.
“All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease, MG, CIDP, D2T RA, SjD and CLE.”
“Other clinical development timelines remain on track for IMVT-1402, including potentially registrational studies in GD, MG, CIDP, and SjD.”
Prepare for potential commercial launch of IMVT-1402 in Graves' disease based on current cash runway and clinical progress.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents were $902.1 million at 2026-Q1 and $797.8 million at 2026-Q2, providing runway to the potential launch of IMVT-1402 in Graves' disease. The cash position supports management's stated runway priority, showing delivering trajectory.
“Current cash balance provides runway to the potential launch of IMVT-1402 in GD.”
“Immunovant's cash position provides runway for announced indications through the potential commercial launch of IMVT-1402 in GD.”
Cease development of batoclimab after Phase 3 failures to concentrate resources on IMVT-1402 clinical programs.
Newly stated in 2026-Q1. Management discontinued batoclimab development after Phase 3 trials failed primary endpoints and shifted focus to IMVT-1402. This is a one-time strategic shift with no subsequent quarterly restatement, reflecting a completed reprioritization.
“Following these results, we discontinued further development of batoclimab across all indications to focus fully on IMVT-1402.”
Control R&D expenses while advancing clinical trials, balancing increased trial costs and wind-down of batoclimab studies.
Stated as a priority in 2 of last 2 quarters. R&D expenses rose from $93.7 million in 2026-Q1 to $142.6 million in 2026-Q2 due to IMVT-1402 clinical activities and batoclimab wind-down costs. Management acknowledges expense management amid clinical progress, showing delivering but with increased spend.
“R&D expenses were $142.6 million, up from $101.2 million, due to IMVT-1402 trials and contract manufacturing, partially offset by batoclimab wind-down.”
“R&D expenses were $142.3 million, compared to $93.7 million, driven by IMVT-1402 clinical trials and $39.0 million related to batoclimab discontinuation.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.